Pre-market Most Active: PHARM.AS Pharming Group €1.71 29 Jan 2026: Volume rises
PHARM.AS stock opens pre-market at €1.71, down 3.93% on heavy activity that makes it one of the most active names on EURONEXT this morning. Volume is 22,173,820.00 shares versus an average of 17,430,073.00, pushing relative volume to 1.27. Traders are watching RUCONEST sales momentum and recent upward revisions in revenue guidance as catalysts. We track valuation and technical signals to show why PHARM.AS is drawing outsized flows in Europe ahead of the company’s next earnings announcement on 12 Mar 2026.
PHARM.AS stock: pre-market price and flow snapshot
PHARM.AS stock trades at €1.71 with an open of €1.80 and a prior close of €1.78. Intraday range is €1.70–€1.82 and the 52-week high stands at €1.82. Market capitalization is €1,191,336,889.00 with 696,688,239.00 shares outstanding. The outsized volume of 22,173,820.00 versus average 17,430,073.00 explains why the name ranks among the most active on EURONEXT this pre-market session.
PHARM.AS stock: valuation and fundamentals
Pharming Group reports EPS -€0.01 and a trailing PE shown as -171.00 given negative near-term earnings. Key ratios: P/S 3.93, P/B 5.16, current ratio 3.16, and debt/equity 0.49. Free cash flow yield is 3.70% and operating margin is 7.27%. These metrics show revenue strength but stretched market multiples for a biotech focused on rare-disease products.
PHARM.AS stock: recent news and revenue drivers
Recent headlines show stronger-than-expected top-line momentum driven by RUCONEST and Joenja demand. Market commentary noted preliminary unaudited 2025 revenues near €376.00 million, above guidance and supporting the sector rotation into biotech source. A separate market alert highlighted a new 1-year high on OTC listings and solid quarterly revenue beats source.
PHARM.AS stock: technicals and trading signals
Technicals show short-term strength: RSI 71.76 (overbought), MACD histogram 0.01, and Bollinger mid €1.45 with upper band €1.55. Momentum indicators and a relative volume spike support active intraday trading. Average price over 50 days is €1.48 and 200-day is €1.16, both below current price, signalling a recent uptrend but higher short-term volatility.
PHARM.AS stock: Meyka grade and model forecast
Meyka AI rates PHARM.AS with a score of 64.16 out of 100 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12‑month target of €1.99, against the current €1.71, implying an upside of 16.20%. Forecasts are model-based projections and not guarantees.
PHARM.AS stock: risks and opportunities for traders
Opportunity: steady RUCONEST revenue and new product demand can sustain momentum and support valuation re-rating. Risk: tight biotech multiples, mixed profitability signals, and a negative short-term PE create downside if guidance slips. Watch the upcoming 12 Mar 2026 earnings date, regulatory updates, and partner announcements, which will likely drive the next liquidity waves.
Final Thoughts
Key takeaways for PHARM.AS stock: the pre-market session shows €1.71 with heavy volume at 22,173,820.00, marking it one of the most active EURONEXT names today. Fundamentals show healthy revenue growth and a current ratio 3.16, but valuation metrics such as P/B 5.16 and a negative PE raise sensitivity to execution. Meyka AI’s model projects a 12‑month price of €1.99, implying 16.20% upside versus the current price; monthly horizon shows €1.64, a small near-term downside. Traders should weigh the momentum trade against company-specific catalysts and sector direction in Healthcare, where average P/E is 34.44. We recommend monitoring intraday liquidity and the 12 Mar 2026 earnings release for fresh guidance. For a live watch and model updates use our Meyka AI-powered market analysis platform and the Pharming stock page on Meyka for real-time signals.
FAQs
What is the current price and volume for PHARM.AS stock?
PHARM.AS stock trades pre-market at €1.71 with volume 22,173,820.00 shares versus average 17,430,073.00, making it highly active on EURONEXT this session.
What valuation metrics should investors watch for PHARM.AS stock?
Watch PE (currently -171.00), P/S 3.93, P/B 5.16, and free cash flow yield 3.70%. These show growth with stretched multiples for a biotech of this size.
What is Meyka AI’s forecast for PHARM.AS stock?
Meyka AI’s forecast model projects a 12‑month price of €1.99 versus current €1.71, implying 16.20% upside. Forecasts are model-based projections and not guarantees.
What catalysts could move PHARM.AS stock next?
Key catalysts include the 12 Mar 2026 earnings report, RUCONEST and Joenja revenue updates, regulatory news, and partnership announcements. Any guidance change will affect trading activity.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
